Company Directory > CDMO > Pyramid Laboratories, Inc.
Pyramid Laboratories is a leading Contract Development and Manufacturing Organization (CDMO) specializing in parenteral (injectable) drug products. The company provides a comprehensive range of services including formulation development, analytical method development, aseptic filling, and lyophilization for both clinical and commercial-stage biopharmaceutical products. Operating out of high-tech facilities in Southern California, Pyramid is known for its expertise in handling complex molecules, including small molecules, proteins, and monoclonal antibodies. They offer end-to-end support from initial drug substance characterization through to final large-scale commercial production and distribution.
CLASSIFICATION
Company Type:CDMO
Industry:CDMO
Sub-Industry:Sterile Injectables / Fill-Finish
SIZE & FINANCIALS
Employees:51-200
Revenue:$25M-$50M
Founded:1988
Ownership:private
Status:operating
FUNDING
Stage:Late Stage
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Service Provider)
Modalities:Small molecule, mAb, Proteins, Peptides, Vaccines
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Confidential partnerships with mid-to-large cap biotech companies for fill-finish services
COMPETITION
Position:Niche Player
Competitors:Catalent, Thermo Fisher Scientific (Patheon), Baxter BioPharma Solutions, Grand River Aseptic Manufacturing, Singota Solutions
LEADERSHIP
Key Executives:
Medhat Gorgy - President & CEO
Ziad Gorgy - Vice President of Operations
Scientific Founders:Medhat Gorgy
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Pyramid Laboratories, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.